Next Article in Journal
Estimation of Drug Cost Avoidance and Pathology Cost Avoidance through Participation in NCIC Clinical Trials Group Phase III Clinical Trials in Canada
Previous Article in Journal
Importance of Cost Estimates and Cost Studies
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cost Trajectories for Cancer Patients

1
Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada
2
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
3
Toronto Rehabilitation Institute, Toronto, ON, Canada
4
Cancer Care Ontario, Toronto, ON, Canada
5
Department of Oncology, McMaster University, Hamilton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(s1), 64-75; https://doi.org/10.3747/co.23.2995
Submission received: 6 November 2015 / Revised: 7 December 2015 / Accepted: 8 January 2016 / Published: 1 February 2016

Abstract

Background: Health care spending is known to be highly skewed, with a small subset of the population consuming a disproportionate amount of health care resources. Patients with cancer are high-cost users because of high incremental health care costs for treatment and the growing prevalence of cancer. The objectives of the present study included characterizing cancer-patient trajectories by cost, and identifying the patient and health system characteristics associated with high health system costs after cancer treatment. Methods: This retrospective cohort study identified Ontario adults newly diagnosed with cancer between 1 April 2009 and 30 September 2010. Costs of health care use before, during, and after cancer episodes were used to develop trajectories of care. Descriptive analyses examined differences between the trajectories in terms of clinical and health system characteristics, and a logistic regression approach identified predictors of being a high-cost user after a cancer episode. Results: Ten trajectories were developed based on whether patients were high- or low-cost users before and after their cancer episode. The most common trajectory represented patients who were low-cost in the year before cancer, survived treatment, and continued to be low-cost in the year after cancer (31.4%); stage ii cancer of the male genital system was the most common diagnosis within that trajectory. Regression analyses identified increases in age and in multimorbidity and low continuity of care as the strongest predictors of high-cost status after cancer. Conclusions: Findings highlight an opportunity to proactively identify patients who might transition to high-cost status after cancer treatment and to remediate that transition.
Keywords: multimorbidity; resource intensity; costs multimorbidity; resource intensity; costs

Share and Cite

MDPI and ACS Style

Wodchis, W.P.; Arthurs, E.; Khan, A.I.; Gandhi, S.; MacKinnon, M.; Sussman, J. Cost Trajectories for Cancer Patients. Curr. Oncol. 2016, 23, 64-75. https://doi.org/10.3747/co.23.2995

AMA Style

Wodchis WP, Arthurs E, Khan AI, Gandhi S, MacKinnon M, Sussman J. Cost Trajectories for Cancer Patients. Current Oncology. 2016; 23(s1):64-75. https://doi.org/10.3747/co.23.2995

Chicago/Turabian Style

Wodchis, W.P., E. Arthurs, A.I. Khan, S. Gandhi, M. MacKinnon, and J. Sussman. 2016. "Cost Trajectories for Cancer Patients" Current Oncology 23, no. s1: 64-75. https://doi.org/10.3747/co.23.2995

APA Style

Wodchis, W. P., Arthurs, E., Khan, A. I., Gandhi, S., MacKinnon, M., & Sussman, J. (2016). Cost Trajectories for Cancer Patients. Current Oncology, 23(s1), 64-75. https://doi.org/10.3747/co.23.2995

Article Metrics

Back to TopTop